Local News

• Synvista Therapeutics appoints William Federici to its Board of Directors  Synvista Therapeutics announces that it has appointed William (Bill) Federici, 49, to its Board of Directors, expanding the board to five members. Mr. Federici joined West Pharmaceutical Services as Vice President and Chief Financial Officer in August of 2003.
  Synvista Therapeutics, Inc. October 10, 2008  
• Wyeth wins Philadelphia diet drug trial involving claim of PPH  Wyeth announced that the jury in the case of Danny Crowder (Individually and as Administrator of the Estate of Edna Faye Crowder) v. Wyeth in the Philadelphia Court of Common Pleas found in favor of Wyeth.
  Wyeth October 10, 2008  
• Boston Scientific announces FDA approval of 2nd-generation TAXUS Liberte Stent  Boston Scientific announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System.
  Boston Scientific Corporation October 10, 2008  
• Introducing Pediatric Care Online(TM)  The American Academy of Pediatrics (AAP) is introducing a revolutionary, next-generation point-of-practice resource to the nation's pediatricians this week as the organization holds its annual National Conference & Exhibition.
  Bristol-Myers Squibb Company October 10, 2008  
• ROTATEQ(R) receives WHO pre-qualification  ROTATEQ(R) (rotavirus vaccine, live, oral, pentavalent), the pentavalent rotavirus vaccine from Merck & Co. that helps prevent rotavirus gastroenteritis in infants and children, has been awarded pre-qualification status by the World Health Organization (WHO).
  Merck & Co., Inc. October 10, 2008  
• Lilly recognized as one of the world's Top Biopharmaceutical Employers  Eli Lilly and Company announced that it has made the list of Top 20 biopharmaceutical employers, according to the prestigious peer-reviewed journal Science.
  Eli Lilly and Company October 10, 2008  
• FDA approves AstraZeneca's Seroquel XR for the treatment of bipolar depression  AstraZeneca announced that the FDA has approved once-daily SEROQUEL XR Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder.
  AstraZeneca October 10, 2008  
• Invitrogen launches Countess(TM)  Invitrogen announced the introduction of a new benchtop instrument, Countess(TM) automated cell counter, which offers a new method of automated cell counting to replace manual cell counting using a glass hemocytometer.
  Invitrogen Corporation October 10, 2008  
• FDA approves new injection site for RISPERDAL(R) CONSTA(R) for schizophrenia treatment  Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R). The U.S. Food and Drug Administration (FDA) has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia.
  Johnson & Johnson October 09, 2008  
• FDA approves new injection site for RISPERDAL(R) CONSTA(R) for schizophrenia treatment  Alkermes announced that patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection).
  Alkermes, Inc. October 09, 2008  

   (next 10 articles)